Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mancuso, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mancuso, M.
Haematologica, Vol 91, Issue 10, 1367-1371
Copyright © 2006 by Ferrata Storti Foundation

Clinical Trial

High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C

ME Mancuso, MG Rumi, E Santagostino, S Linari, A Coppola, PM Mannucci, M Colombo, and

Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialities, University of Milan and IRCCS Maggiore Hospital, Mangiagalli, Italy.

BACKGROUND AND OBJECTIVES: Eradication of hepatitis C virus (HCV) is particularly difficult in patients with hemophilia. In this open, prospective, multicenter trial, the efficacy and tolerability of the combination therapy with pegylated interferon alpha2b (Peg-IFNalpha2b) plus ribavirin was evaluated in 64 human immunodeficiency virus (HIV) seronegative adult hemophiliacs with chronic hepatitis C naive to previous antiviral therapy. DESIGN AND METHODS: Peg-IFNalpha2b was administered at a dose of 1.5 microg/kg subcutaneously once weekly plus oral ribavirin 800-1200 mg/day, for 24 weeks to patients with HCV genotypes 2 and 3 (n=22, 34%) or for 48 weeks to those with genotypes 1 and 4 (n=42, 66%). RESULTS: Nine patients (14%) did not complete the study because of non-compliance (n=6) or side-effects such as decompensated diabetes, alanine aminotransferase flares and severe vomiting (n=3). Twenty-eight patients (44%) required dose reduction of either drug. Six months after stopping treatment a sustained virological response was achieved in 40 patients (63%), 19 with genotype 2 or 3 (86%) and 21 with genotype 1 or 4 (50%). A sustained virological response was significantly associated with an early virological response (p<0.0001), HCV genotypes 2 or 3 (p=0.008), no clinical evidence of cirrhosis (p=0.02) and higher pre-treatment serum alanine aminotransferase (p=0.016). INTERPRETATION AND CONCLUSIONS: These results show that combination therapy with Peg-IFNalpha2b plus ribavirin is highly efficacious in hemophiliacs with chronic hepatitis C.


This article has been cited by other articles:


Home page
 haematolHome page
P. Harmatz, M. M. Jonas, J. L. Kwiatkowski, E. C. Wright, R. Fischer, E. Vichinsky, P. J. Giardina, E. J. Neufeld, J. Porter, N. Olivieri, et al.
Safety and efficacy of pegylated interferon {alpha}-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia
Haematologica, August 1, 2008; 93(8): 1247 - 1251.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Franchini, C. Mengoli, D. Veneri, R. Mazzi, G. Lippi, and M. Cruciani
Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis
J. Antimicrob. Chemother., June 1, 2008; 61(6): 1191 - 1200.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.